NEWS:
LATEST STUDIES:
Search result
7 Results found
Traitement des enfants de plus de 1 an porteurs d.un neuroblastome localisé inopérable d.emblée et sans amplification de l.oncogène N-myc
Treatment of children over 1 year with unresectable localised neuroblastoma without MYCN amplification
Etude de phase II du Temozolide (TEMODAL) chez les patients de plus de 1 an porteurs d.un neuroblastome de haut risque réfractaire ou en rechute
Phase II study of temozolomide (Temodal) in children over 1 year of age with relapsed or refractory high risk neuroblastoma
Etude européenne des neuroblastomes chez le nourrisson de moins de 12 mois
Combination Chemotherapy in treating infants younger than twelve months with newly diagnosed Neuroblastoma
Studio "di ponte" utilizzando l'anticorpo CH14.18/CHO nei bambini con neuroblastoma refrattaria
Bridging study using CH14.18/CHO antibody in children with refractoryneuroblastoma
Studio fase I/II per l'identificazione della dose, per la valutazione del profilo di farmacocinetica e sicurezza di epirubicina in pazienti in età pediatrica affetti da tumori solidi o linfomi recidivati o refrattari alle terapie convenzionali e per la valutazione dell.efficacia in pazienti in età pediatrica affetti da neuroblastoma recidivato o refrattario a terapia convenzionale.
Phase I/II study to identify the dose, to evaluate the pharmacokinetic and safety profile of epirubicin in children with solid tumors or lymphomas that have relapsed or become refractory to conventional therapy, and to evaluate its efficacy in paediatric patients with neuroblastoma that has relapsed or become refractory to conventional therapy .
Topotecan-Vincristine-Doxorubicin nei bambini con neuroblastoma stadio 4 che non rispondono a COJEC
Topotecan-Vincristine-Doxorubicin in children with stage 4 neuroblastoma failing to respond to COJEC
A Phase II Study of Topotecan-Vincristine-Doxorubicin (TVD) in children with stage 4 neuroblastoma failing to respond to COJEC
Results 7 of 7 found
1